NeuroPace

NeuroPace reported Q2 2026 revenue of $22.8 million, with RNS System revenue of $22.5 million representing 21.3% year-over-year growth. GAAP net loss narrowed to $6.2 million from $10.0 million in Q2 2025. Adjusted EBITDA loss improved to $2.8 million from $4.9 million. Operationally, the company launched ECoG Assistant, an AI-based clinical decision support tool leveraging proprietary intracranial EEG data; published 18-month NAUTILUS randomized controlled trial results showing 77% median reduction in generalized tonic-clonic seizures in drug-resistant idiopathic generalized epilepsy; and reached new highs in active prescribers, accounts, and patient pipeline. The company discontinued its DIXI Medical product operations. Management raised full-year 2026 revenue guidance to $99.5–101.5 million (21–23% RNS growth) and upgraded adjusted gross margin guidance to 82.0–83.0%. Preparation for an FDA submission regarding IGE indication expansion remains on track with 24-month NAUTILUS data showing 100% median reduction in seizures among evaluable patients.

No articles ingested yet for NeuroPace. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.